|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits with banks | ||||||||||||||||||||
| Federal funds sold and securities purchased under agreements to resell | ||||||||||||||||||||
| Trading securities | ||||||||||||||||||||
| Securities available for sale at fair value | ||||||||||||||||||||
| Securities held to maturity (fair value of $1,038 and $1,073, respectively) | ||||||||||||||||||||
| Loans held for sale (including $88 and $151 at fair value, respectively) | ||||||||||||||||||||
| Loans and leases | ||||||||||||||||||||
| Allowance for loan and lease losses | ||||||||||||||||||||
| Net loans and leases | ||||||||||||||||||||
| Premises and equipment | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Noninterest-bearing deposits | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Trading liabilities | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Term borrowings | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Preferred stock, Non-cumulative perpetual, no par value; authorized 5,000,000 shares; issued 7,000 and 8,750 shares, respectively | ||||||||||||||||||||
| Common stock, $0.625 par value; authorized 700,000,000 shares; issued 473,919,939 and 484,825,395 shares, respectively | ||||||||||||||||||||
| Capital surplus | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss, net | ||||||||||||||||||||
| FHN shareholders' equity | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
| Preferred stock, shares issued (in shares) |
Loading...
